Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 297

1.

Identification of lead compounds as antagonists of protein Bcl-xL with a diversity-oriented multidisciplinary approach.

Di Micco S, Vitale R, Pellecchia M, Rega MF, Riva R, Basso A, Bifulco G.

J Med Chem. 2009 Dec 10;52(23):7856-67. doi: 10.1021/jm9010687.

PMID:
19852471
2.

The discovery of antibacterial agents using diversity-oriented synthesis.

Galloway WR, Bender A, Welch M, Spring DR.

Chem Commun (Camb). 2009 May 14;(18):2446-62. doi: 10.1039/b816852k. Epub 2009 Apr 1. Review.

PMID:
19532856
3.

Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.

Petros AM, Dinges J, Augeri DJ, Baumeister SA, Betebenner DA, Bures MG, Elmore SW, Hajduk PJ, Joseph MK, Landis SK, Nettesheim DG, Rosenberg SH, Shen W, Thomas S, Wang X, Zanze I, Zhang H, Fesik SW.

J Med Chem. 2006 Jan 26;49(2):656-63.

PMID:
16420051
4.

Design, synthesis, and computational studies of inhibitors of Bcl-XL.

Park CM, Oie T, Petros AM, Zhang H, Nimmer PM, Henry RF, Elmore SW.

J Am Chem Soc. 2006 Dec 20;128(50):16206-12.

PMID:
17165773
5.

Diversity-oriented synthesis; a spectrum of approaches and results.

Spandl RJ, Bender A, Spring DR.

Org Biomol Chem. 2008 Apr 7;6(7):1149-58. doi: 10.1039/b719372f. Epub 2008 Feb 19. Review.

PMID:
18362950
6.

Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening.

Mukherjee P, Desai P, Zhou YD, Avery M.

J Chem Inf Model. 2010 May 24;50(5):906-23. doi: 10.1021/ci1000373.

PMID:
20392095
7.

Docking methods for structure-based library design.

Cavasotto CN, Phatak SS.

Methods Mol Biol. 2011;685:155-74. doi: 10.1007/978-1-60761-931-4_8.

PMID:
20981523
8.

A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.

Levoin N, Vo DD, Gautier F, Barillé-Nion S, Juin P, Tasseau O, Grée R.

Bioorg Med Chem. 2015 Apr 15;23(8):1747-57. doi: 10.1016/j.bmc.2015.02.060. Epub 2015 Mar 6.

9.

Design, synthesis, and interaction study of quinazoline-2(1H)-thione derivatives as novel potential Bcl-xL inhibitors.

Feng Y, Ding X, Chen T, Chen L, Liu F, Jia X, Luo X, Shen X, Chen K, Jiang H, Wang H, Liu H, Liu D.

J Med Chem. 2010 May 13;53(9):3465-79. doi: 10.1021/jm901004c.

PMID:
20405848
10.

Structure-based library design in efficient discovery of novel inhibitors.

Yan S, Selliah R.

Methods Mol Biol. 2011;685:175-90. doi: 10.1007/978-1-60761-931-4_9.

PMID:
20981524
11.

Discovery of small molecule inhibitors of protein-protein interactions using combined ligand and target score normalization.

Casey FP, Pihan E, Shields DC.

J Chem Inf Model. 2009 Dec;49(12):2708-17. doi: 10.1021/ci900294x.

PMID:
19994847
12.

Isolation of a small-molecule inhibitor of the antiapoptotic protein Bcl-xL from a DNA-encoded chemical library.

Melkko S, Mannocci L, Dumelin CE, Villa A, Sommavilla R, Zhang Y, Grütter MG, Keller N, Jermutus L, Jackson RH, Scheuermann J, Neri D.

ChemMedChem. 2010 Apr 6;5(4):584-90. doi: 10.1002/cmdc.200900520.

PMID:
20229565
13.

Targeting oncogenic protein-protein interactions by diversity oriented synthesis and combinatorial chemistry approaches.

Tzakos AG, Fokas D, Johannes C, Moussis V, Hatzimichael E, Briasoulis E.

Molecules. 2011 May 27;16(6):4408-27. doi: 10.3390/molecules16064408. Review.

14.

Isosteric exchange of the acylsulfonamide moiety in Abbott's Bcl-XL protein interaction antagonist.

Dömling A, Antuch W, Beck B, Schauer-Vukasinović V.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):4115-7. doi: 10.1016/j.bmcl.2008.05.096. Epub 2008 May 29.

PMID:
18583128
15.

Fragment-based deconstruction of Bcl-xL inhibitors.

Barelier S, Pons J, Marcillat O, Lancelin JM, Krimm I.

J Med Chem. 2010 Mar 25;53(6):2577-88. doi: 10.1021/jm100009z.

PMID:
20192224
16.

Structure-activity relationship studies of phenanthridine-based Bcl-XL inhibitors.

Bernardo PH, Wan KF, Sivaraman T, Xu J, Moore FK, Hung AW, Mok HY, Yu VC, Chai CL.

J Med Chem. 2008 Nov 13;51(21):6699-710. doi: 10.1021/jm8005433. Epub 2008 Oct 17.

PMID:
18925736
17.

Fragment-based ligand discovery.

Fischer M, Hubbard RE.

Mol Interv. 2009 Feb;9(1):22-30. doi: 10.1124/mi.9.1.7. Review.

PMID:
19299661
18.

From fragment screening to potent binders: strategies for fragment-to-lead evolution.

Eitner K, Koch U.

Mini Rev Med Chem. 2009 Jul;9(8):956-61. Review.

PMID:
19601891
19.

Selecting chemicals: the emerging utility of DNA-encoded libraries.

Clark MA.

Curr Opin Chem Biol. 2010 Jun;14(3):396-403. doi: 10.1016/j.cbpa.2010.02.017. Epub 2010 Mar 26. Review.

PMID:
20346729
20.

[Fragment-based lead discovery from smaller fragments to functional ligand].

Hatayama A, Habashita H.

Tanpakushitsu Kakusan Koso. 2009 Sep;54(12 Suppl):1611-6. Review. Japanese. No abstract available.

PMID:
21089596

Supplemental Content

Support Center